OXFORD BIOMEDCL Net Income 2021-2020 | OXBDF

OXFORD BIOMEDCL net income from 2021 to 2020. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
OXFORD BIOMEDCL Annual Net Income
(Millions of US $)
2020 $-8
2019 $-21
2018 $10
2017 $-12
2016 $-23
2015 $-20
OXFORD BIOMEDCL Quarterly Net Income
(Millions of US $)
2020-12-31
2020-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.576B $0.113B
Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00